实时定量PCR检测Bcl-2/IgH融合基因在淋巴瘤中的应用  

Application of Real-time Quantitative PCR Detecting Bcl-2/IgH Fusion Gene in Lymphoma

作　　者：徐明[1] 张学美[1] 

机构地区：[1]昆明医学院第一附属医院血液科,昆明650031

出　　处：《医学综述》2008年第6期811-813,共3页Medical Recapitulate

摘　　要：Bcl-2/IgH融合基因是淋巴瘤的肿瘤特异性标志,见于85%～90%的滤泡性淋巴瘤及30%的弥漫性大B细胞淋巴瘤患者。大量研究表明,该融合基因与滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤有很好的相关性,对Bcl-2/IgH的定量检测能反应淋巴瘤的临床进程。现就实时定量PCR技术对Bcl-2/IgH融合基因的检测在淋巴瘤的分期、疗效评价、预测复发和预后评估等方面的临床意义进行综述。The Bcl-2/IgH fusion gene is the specific mark of malignant lymphoma.It was expressed in 85%~90% cases of follicular lymphoma（FL） and 30% diffuse large B-cell lymphoma（DLBCL）.Studies showed that this fusion gene has good correlativity with follicular lymphoma and diffuse large B-cell lymphoma,and the quantitative detection of this fusion gene can reflect the clinical process of lymphoma.This article reviews clinical significance of Bcl-2/IgH fusion gene detection by RQ-PCR in the staging,evaluation of curative effect,prediction of recurrence,and prognostic evaluation.

关 键 词：BCL-2/IGH 融合基因 淋巴瘤 实时定量聚合酶链反应 

分 类 号：R733.4[医药卫生—肿瘤] R730.43[医药卫生—临床医学]